AI Article Synopsis
Article Abstract
Opioid medicines prescribed on a long-term basis for opioid dependence syndrome have historically been deemed « substitution treatments » and misunderstood as involving the "replacement of an illicit drug by a legal drug". Prior authorisation schemes, in addition to ordinary procedures for authorising medicines and supervising professionals, interfere with access to treatment. In order to guide the countries in their efforts to modernise their regulations, the Pompidou Group mandated a group of health and legal experts, who identified 62 guiding principles and developed four strategic recommendations : 1) the removal of prior authorisation schemes, 2) the removal of financial barriers, 3) supervision by a national consultative body and 4) The adoption of neutral, precise and respectful terminology.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Spontaneous oxycodone withdrawal disrupts sleep, diurnal, and electrophysiological dynamics in rats.
PLoS One
January 2025
Dept. of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, United States of America.
Opioid dependence is defined by an aversive withdrawal syndrome upon drug cessation that can motivate continued drug-taking, development of opioid use disorder, and precipitate relapse. An understudied but common opioid withdrawal symptom is disrupted sleep, reported as both insomnia and daytime sleepiness. Despite the prevalence and severity of sleep disturbances during opioid withdrawal, there is a gap in our understanding of their interactions.
View Article and Find Full Text PDFSelf-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.
Addiction
January 2025
Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, CA, USA.
Background And Aims: The opioid crisis continues to exert a tremendous toll in North America, with existing interventions often falling short of addressing ongoing needs. Psychedelics are emerging as a possible alternative therapy for mental health and substance use disorders. This study aimed to gather insights on how people use or are considering using psychedelics to manage opioid use disorder (OUD), how these experiences are perceived to impact opioid use and what these lessons imply for future research and practice.
View Article and Find Full Text PDFNeural Variability and Cognitive Control in Individuals With Opioid Use Disorder.
JAMA Netw Open
January 2025
Interdepartmental Neuroscience Program, Yale University, New Haven, Connecticut.
Importance: Opioid use disorder (OUD) impacts millions of people worldwide. Prior studies investigating its underpinning neural mechanisms have not often considered how brain signals evolve over time, so it remains unclear whether brain dynamics are altered in OUD and have subsequent behavioral implications.
Objective: To characterize brain dynamic alterations and their association with cognitive control in individuals with OUD.
Opioid agonist therapy discontinuation in British Columbia: a cross-sectional study of people who access harm reduction services.
BMJ Open
January 2025
The University of British Columbia, Vancouver, British Columbia, Canada
Objectives: This study evaluates the prevalence and correlates of opioid agonist therapy (OAT) discontinuation across British Columbia (BC), using a sample of individuals who used substances and accessed harm reduction sites.
Design: This study uses data from the 2019 cross-sectional Harm Reduction Client Survey (HRCS).
Setting: The 2019 survey was administered from October to December at 22 harm reduction supply distribution sites across the 5 Regional Health Authorities of BC.
Prescription opioid dispensing rates in the 12-months post-discharge after acute spinal cord injury: An observational study.
J Spinal Cord Med
January 2025
The Hopkins Centre, Griffith University, Brisbane, Australia.
Objectives: To determine rates of opioid and concomitant antidepressant, anticonvulsant and benzodiazepine dispensing in the post-discharge period, after acute spinal cord injury (SCI).
Design: Single-center prospective cohort study with 12-month linked pharmaceutical data.
Setting: Community pharmaceutical dispensing.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!